Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
+0.54 (3.98%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.43 - 14.34
52 week 6.11 - 25.60
Open 13.43
Vol / Avg. 674,697.00/585,434.00
Mkt cap 720.37M
P/E     -
Div/yield     -
EPS -1.26
Shares 51.02M
Beta     -
Inst. own 65%
Aug 4, 2015
Q2 2015 Regulus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Regulus Therapeutics Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Regulus Therapeutics Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Regulus Therapeutics Inc Earnings Release
May 6, 2015
Regulus Therapeutics Inc at Deutsche Bank Health Care Conference
Apr 15, 2015
Regulus Therapeutics Inc at Needham Healthcare Conference
Mar 4, 2015
Regulus Therapeutics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -344.93% -739.08%
Operating margin -349.57% -743.62%
EBITD margin - -566.05%
Return on average assets -34.55% -38.49%
Return on average equity -41.68% -50.28%
Employees 85 -
CDP Score - -


Suite 210, 3545 John Hopkins Court
United States - Map
+1-858-2026300 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regulus Therapeutics Inc. is a pre-clinical stage, biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, molecules that play a critical role in regulating key biological pathways. It uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. Its operations include acquiring and in-licensing rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. In January 2014, it established Regulus microMarkers, a research and development division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline. Through its microRNA target identification and validation efforts it has developed technologies for microRNA profiling and analysis of human clinical samples such as tissue.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Neil W. Gibson Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David L. Szekeres Chief Business Officer, General Counsel, Corporate Secretary
Age: 41
Bio & Compensation  - Reuters
Paul C. Grint M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 61
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 57
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Bruce L. A. Carter Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Mark G. Foletta CPA Independent Director
Age: 54
Bio & Compensation  - Reuters